secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001193125-25-223262
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista closes $143.75M convertible notes offering; net proceeds ~$139M for EKTERLY
--------------------------------------------------------------------------------

- Issued $143.75M in 3.250% Convertible Senior Notes due 2031, including full exercise of $18.75M greenshoe.
- Net proceeds ~$139M after discounts and expenses; used for working capital and EKTERLY commercialization.
- Initial conversion rate 59.4919 shares/$1,000 (conversion price ~$16.81), 30% premium over $12.93 close.
- Notes are senior, unsecured, callable after Oct 5, 2028 if stock price meets 130% conversion price threshold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525223262/0001193125-25-223262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525223262/d83242d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-223262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer